Cattleya Nery, NP
Primary Care · Chehalis, WANPI 1841919057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,030 and has fallen 98.3% since, to $18 in 2025.
Across 72 payments — averaging $21.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$271
- Lilly USA, LLC$256
- AbbVie$235
- GSK$193
- Sumitomo Pharma America, Inc.$125
- Novo Nordisk$69
- plus $415 from 15 others
What the payments were for
- Food & beverage$1,563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 10 | $271 |
| Lilly USA, LLC | 14 | $256 |
| AbbVie | 15 | $235 |
| GSK | 6 | $193 |
| Sumitomo Pharma America, Inc. | 1 | $125 |
| Novo Nordisk | 4 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Sanofi Pasteur Inc. | 2 | $50 |
| Merck | 2 | $41 |
| Boston Scientific | 2 | $37 |
| Halozyme Inc | 2 | $32 |
| Amgen | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Covis Pharma GmbH | 1 | $22 |
| Boehringer Ingelheim | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Antares Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,563 in reported general payments places this provider in the 85th percentile of 94 primary care providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $13,258 |
| TrulicityDulaglutide | 16 | $12,110 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,479 |
| JardianceEmpagliflozin | 19 | $6,162 |
| GemtesaVibegron | 11 | $3,756 |
| MovantikNaloxegol Oxalate | 11 | $3,504 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $2,163 |
| Potassium Chloride | 23 | $854 |
| Tizanidine Hcl | 37 | $847 |
| Quetiapine Fumarate | 45 | $770 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 31 | $607 |
| Mirtazapine | 19 | $538 |
| Ondansetron OdtOndansetron | 13 | $515 |
| Gabapentin | 45 | $513 |
| Atorvastatin Calcium | 44 | $512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $13,25830 claims |
| Lilly USA, LLCTrulicity | $256 | $12,11016 claims |
| GSKTrelegy Ellipta | $193 | $7,47911 claims |
| Boehringer IngelheimJardiance | $19 | $6,16219 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $3,75611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 94 primary care providers in Washington.
Other primary care in Chehalis
- Abubakar Abdul-RahmanSeattle$27K
- Junghee CheLakewood$20K
- Margaret StewartMill Creek$14K
- Rhonna LeeSpokane$13K
- Joan ZimmerSpokane$12K
- Kimberly RianoOlympia$8K
- James PittmanSpokane$6K
- Shannon ZawilskiPuyallup$4K
- Laura RaykowskiMontesano$3K
- Sara AppudorayPuyallup$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.